GlassScriptPhysician profile
Mohamad B Kadri
NPI 1538192166
$5,020.36
in general payments reported to CMS, 2019-2025
29 companies · $857 in 2025
The $857 reported for 2025 was more than what 81% of Adolescent Medicine (Family Medicine) providers received nationally (typical 2025 total: $135).
See the full distribution for Adolescent Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $61.97 · 2023: $2,195 · 2024: $1,906 · 2025: $857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,940 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,939.54 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $684.72 | 2023-2025 | Dupixent |
| Amgen INC. | $500.18 | 2023-2024 | Otezla, Repatha |
| Genzyme Corporation | $486.52 | 2023-2025 | |
| Cranial Technologies, INC | $422.70 | 2023-2025 | Doc Band |
| Astrazeneca Pharmaceuticals LP | $339.29 | 2023-2024 | Airsupra, Breztri, Lokelma |
| Merck Sharp & Dohme LLC | $301.66 | 2023-2025 | Vaxneuvance, Gardasil 9, Enflonsia |
| Lilly USA, LLC | $208.86 | 2023-2024 | Mounjaro |
| Glaxosmithkline, LLC. | $190.81 | 2022-2024 | Shingrix, Rotarix, Pediarix |
| Dexcom, INC. | $131.97 | 2023 | Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $131.46 | 2023 | Tepezza |
| Halozyme INC | $127.39 | 2023 | |
| Phathom Pharmaceuticals, INC. | $125.00 | 2025 | Voquezna |
| Aimmune Therapeutics, INC. | $124.74 | 2024 | |
| Nestle Healthcare Nutrition INC. | $124.74 | 2023 | |
| Janssen Pharmaceuticals, INC | $121.85 | 2023 | Xarelto |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $121.34 | 2024 | Wegovy |
| Aurinia Pharma U.S., INC. | $119.76 | 2023 | Lupkynis |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $117.13 | 2023 | |
| Smith+Nephew, INC. | $115.24 | 2024 | Collagenase Santyl |
| Axsome Therapeutics, INC. | $113.39 | 2023 | Auvelity |
| Antares Pharma, INC. | $112.40 | 2024 | Xyosted |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.34 | 2023 | Jardiance |
| Sanofi Pasteur INC. | $53.96 | 2022-2024 | |
| Pfizer INC. | $43.15 | 2024 | |
| Alkermes, INC. | $23.75 | 2025 | Aristada, Lybalvi |
| Cipher Pharmaceuticals US LLC | $22.21 | 2025 | Spinosad, Natroba |
| Seqirus USA INC | $20.79 | 2025 | Flucelvax |
| Alk-Abello, INC | $17.62 | 2023 | Ragwitek, Odactra, Grastek |
| Sobi, INC | $15.39 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohamad Kadri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.